US2012178780A1PendingUtilityA1

Raf kinase inhibitors

Individually held — no corporate assignee on recordPriority: May 23, 1997Filed: Mar 19, 2012Published: Jul 12, 2012
Est. expiryMay 23, 2017(expired)· nominal 20-yr term from priority
C07D 207/34C07D 409/12C07D 417/12C07D 333/38C07D 307/68A61P 35/00C07D 471/04
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . A method according to  claim 1 , comprising administering a compound of the formulae 
       
         
           
           
               
               
           
         
       
     
     
         3 . A method according to  claim 1 , comprising administering a compound of the formula 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         4 . A method according to  claim 1 , comprising administering a compound of formulae 
       
         
           
           
               
               
           
         
       
     
     
         5 . A method according to  claim 1 , comprising administering a compound of formulae 
       
         
           
           
               
               
           
         
       
     
     
         6 . A method according to  claim 1 , comprising administering a compound of formulae 
       
         
           
           
               
               
           
         
       
     
     
         7 . A method according to  claim 1 , comprising administering a compound of formulae 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         8 . A compound of the formulae 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         9 . A compound according to  claim 8 , of the formulae 
       
         
           
           
               
               
           
         
       
     
     
         10 . A compound according to  claim 8 , of the formulae 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         11 . A compound according to  claim 8 , of the formulae 
       
         
           
           
               
               
           
         
       
     
     
         12 . A compound according to  claim 8 , of the formulae 
       
         
           
           
               
               
           
         
       
     
     
         13 . A compound according to  claim 8 , of the formulae 
       
         
           
           
               
               
           
         
       
     
     
         14 . A compound according to  claim 8 , of the formulae 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         15 . A pharmaceutical composition comprising a compound according to  claim 8  and a physiologically acceptable carrier. 
     
     
         16 . A pharmaceutical composition comprising a compound according to  claim 14  and a physiologically acceptable carrier. 
     
     
         17 . A pharmaceutical composition comprising a compound according to  claim 8  and a physiologically acceptable carrier, in sterile form.

Join the waitlist — get patent alerts

Track US2012178780A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.